secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVEO PHARMACEUTICALS, INC. (—)
CIK:        0001325879
Form:       8-K
Filed at:   2023-01-19T23:59:59+00:00
Accession:  0001193125-23-010990
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVEO Pharmaceuticals acquired by LG Chem for $15 per share in all-cash deal; stock to be delisted
--------------------------------------------------------------------------------

- Total aggregate consideration of ~$570.6M for shares and stock option settlement.
- Loan agreement terminated; $3.18M in prepayment and end-of-term charges paid.
- AVEO shares will be suspended from Nasdaq and deregistered with SEC.
- Board resigned; Jaywin Lee becomes sole director; new CFO named on interim basis.
- AVEO continues operations under AVEO Oncology name, led by existing CEO Michael Bailey.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/0001193125-23-010990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1325879/000119312523010990/d450299d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-010990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer